ATE244565T1 - Verwendung von 2-aryl-3-aroylbenzo(b)thiophene zur behandlung des oestrogenenthaltungssyndroms - Google Patents

Verwendung von 2-aryl-3-aroylbenzo(b)thiophene zur behandlung des oestrogenenthaltungssyndroms

Info

Publication number
ATE244565T1
ATE244565T1 AT98309228T AT98309228T ATE244565T1 AT E244565 T1 ATE244565 T1 AT E244565T1 AT 98309228 T AT98309228 T AT 98309228T AT 98309228 T AT98309228 T AT 98309228T AT E244565 T1 ATE244565 T1 AT E244565T1
Authority
AT
Austria
Prior art keywords
aroylbenzo
abstention
thiophene
syndrome
aryl
Prior art date
Application number
AT98309228T
Other languages
English (en)
Inventor
George Joseph Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE244565T1 publication Critical patent/ATE244565T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98309228T 1997-11-14 1998-11-11 Verwendung von 2-aryl-3-aroylbenzo(b)thiophene zur behandlung des oestrogenenthaltungssyndroms ATE244565T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6585297P 1997-11-14 1997-11-14

Publications (1)

Publication Number Publication Date
ATE244565T1 true ATE244565T1 (de) 2003-07-15

Family

ID=22065569

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98309228T ATE244565T1 (de) 1997-11-14 1998-11-11 Verwendung von 2-aryl-3-aroylbenzo(b)thiophene zur behandlung des oestrogenenthaltungssyndroms

Country Status (21)

Country Link
US (2) US6156786A (de)
EP (1) EP0920863B1 (de)
JP (1) JP2001523675A (de)
KR (1) KR20010031904A (de)
CN (1) CN1278812A (de)
AT (1) ATE244565T1 (de)
AU (1) AU748394B2 (de)
BR (1) BR9812780A (de)
CA (1) CA2309824A1 (de)
DE (1) DE69816244D1 (de)
EA (1) EA200000520A1 (de)
HR (1) HRP20000287A2 (de)
HU (1) HUP0004413A3 (de)
ID (1) ID24978A (de)
IL (1) IL135509A0 (de)
NO (1) NO20002370L (de)
NZ (1) NZ503990A (de)
PL (1) PL340432A1 (de)
TR (1) TR200001290T2 (de)
WO (1) WO1999025706A1 (de)
ZA (1) ZA9810215B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US6096781A (en) 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
ID24978A (id) * 1997-11-14 2000-08-31 Lilly Co Eli 2-ARYL-3-AROYLBENZO (b) THIOPHENES BERGUNA UNTUK PENGOBATAN SINDROM DEPRIVASI ESTROGEN
US6258826B1 (en) 1998-10-13 2001-07-10 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
WO2011132194A1 (en) * 2010-04-19 2011-10-27 Hetero Research Foundation Process for the preparation of raloxifene hydrochloride
ES2857196T3 (es) 2012-10-24 2021-09-28 The Board Of Trustees Of The Univ Of Illionis Composiciones y métodos para tratar trastornos médicos relacionados con estrógenos
CA2928173C (en) 2012-10-24 2021-10-19 The Board Of Trustees Of The University Of Illinois Compositions comprising benzothiophene derivatives and use thereof for treatment of estrogen-related medical disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
AR003930A1 (es) * 1995-02-28 1998-09-30 Lilly Co Eli Procedimiento para preparar compuestos de 2-fenil-3-fenoxi o feniltio-benzotiofeno y sales farmaceuticamente aceptables, compuestos intermediarios de aplicación exclusiva en dicho procedimiento y metodo para preparar los compuestos intermediarios mencionados
US5514703A (en) * 1995-03-13 1996-05-07 Eli Lilly And Company Benzothiophene compounds useful for inhibiting lipoxygenase
US5514704A (en) * 1995-03-13 1996-05-07 Eli Lilly And Company Benzothiophenes to inhibit leukotrienes
US5532382A (en) * 1995-03-13 1996-07-02 Eli Lilly And Company Benzothiophenes substituted at the 3-carbonyl
DK0842169T3 (da) * 1995-06-26 2001-01-29 Lilly Co Eli Benzothiophenforbindelser
ID24978A (id) * 1997-11-14 2000-08-31 Lilly Co Eli 2-ARYL-3-AROYLBENZO (b) THIOPHENES BERGUNA UNTUK PENGOBATAN SINDROM DEPRIVASI ESTROGEN

Also Published As

Publication number Publication date
KR20010031904A (ko) 2001-04-16
HUP0004413A2 (hu) 2001-08-28
ZA9810215B (en) 2000-05-09
CA2309824A1 (en) 1999-05-27
PL340432A1 (en) 2001-02-12
JP2001523675A (ja) 2001-11-27
WO1999025706A1 (en) 1999-05-27
AU748394B2 (en) 2002-06-06
EA200000520A1 (ru) 2000-10-30
NZ503990A (en) 2002-05-31
EP0920863B1 (de) 2003-07-09
EP0920863A1 (de) 1999-06-09
HUP0004413A3 (en) 2002-12-28
IL135509A0 (en) 2001-05-20
NO20002370L (no) 2000-07-05
HRP20000287A2 (en) 2000-08-31
DE69816244D1 (de) 2003-08-14
US6403615B1 (en) 2002-06-11
ID24978A (id) 2000-08-31
TR200001290T2 (tr) 2000-09-21
CN1278812A (zh) 2001-01-03
US6156786A (en) 2000-12-05
NO20002370D0 (no) 2000-05-05
BR9812780A (pt) 2000-10-03
AU1385899A (en) 1999-06-07

Similar Documents

Publication Publication Date Title
DE69738815D1 (de) Verwendung von Cyclooxygenase-2 Inhibitoren zur Behandlung und Vorbeugung von Neoplasia
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
DE69128516D1 (de) Neue Mercaptoacetylamid-Derivate zur Verwendung als Enkephalinase- und ACE-Hemmer
ATE266623T1 (de) Caspase inhibitoren und deren verwendung
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
ATE232874T1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
DE69816244D1 (de) Verwendung von 2-Aryl-3-aroylbenzo(b)thiophene zur Behandlung des Oestrogenenthaltungssyndroms
ATE263771T1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
DE60142313D1 (de) Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen
NO20002371L (no) 2-Arylbenzo[b]tiofener til behandling av østrogen- deprivasjonssyndrom
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69730796D1 (de) Naphthylverbindungen, Zusammensetzungen und Verfahren
NO893249D0 (no) Cykliske svovelinneholdende forbindelser.
ATE267018T1 (de) Verwendung von peptidverbindungen zur behandlung von sle
DE60007078D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung von bulimia nervosa
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
ATE265854T1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.
DE69727529D1 (de) Benzothiophenverbindungen, Zwischenprodukte, Zusammensetzungen und Methode
EA199801012A1 (ru) Производные полигидроксифенола, содержащие их лекарственные композиции и применение указанных веществ для профилактики и лечения заболеваний костей и хрящей
DE50003481D1 (de) Verwendung von schmutzablösenden formulierungen zur behandlung von oberflächen
DE69711528D1 (de) Naphthofluorenverbindungen, Zwischenverbindungen, Zusammensetzungen und Verfahren
DE69808607D1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
DE69819503D1 (de) Verwendung von 7-apha-methyl-17-alpha-ethynyl-estrane derivaten zur behandlung von atherosclerose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties